Innovex International Inc. American Depositary Receipt Prospectus (2026-02-25 Edition)

Filed Pursuant to Rule 424(b)(7)Registration Number 333-282178 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectussupplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buythese securities in any jurisdiction where such offer or sale is not permitted. Subject to completion. dated February 25, 2026. Preliminary prospectus supplement(To Prospectus dated October1, 2024) 5,750,000 shares Innovex International, Inc. Common stock The selling stockholders identified in this prospectus supplement (the “selling stockholders”) are offering 5,750,000 shares of commonstock, par value $0.01 per share (“common stock”), of Innovex International, Inc. (the “Company,” “we,” “us” and “our”). We will notreceive any proceeds from the sale of shares by the selling stockholders. Subject to the completion of this offering, we intend to purchase from the underwriters the lesser of (i) 10% and (ii) $15 million of theshares of our common stock that are the subject of this offering at the price per share to be received by the selling stockholders in thisoffering. Assuming we repurchase 10% of the shares of common stock that are the subject of this offering, we would purchase 575,000shares of common stock in this offering. We refer to this proposed repurchase as the “Share Repurchase.” The closing of this offering is The underwriters may also purchase up to an additional 862,500 shares of common stock from the selling stockholders at the publicoffering price less the underwriting discount set forth below within 30 days following the date of this prospectus supplement. We will notreceive any proceeds from the sale of shares by the selling stockholders if the underwriters exercise their option to purchase additional The common stock is listed on the NYSE under the symbol “INVX”. The last sale price of the common stock as reported by the NYSE onFebruary 24, 2026 was $28.90 per share. Investing in the common stock involves risks, including those described in the “Risk Factors” section beginning on page S-5 ofthis prospectus supplement, on page2 of the accompanying prospectus and in the documents incorporated by reference in thisprospectus supplement and the accompanying prospectus. Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved ordisapproved of these securities or passed upon the accuracy or adequacy of the disclosures in the prospectus. Anyrepresentation to the contrary is a criminal offense. PiperSandler Jefferies Citigroup J.P.Morgan Table of contents Prospectus Table of Contents About this prospectus supplement This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering andsupplements and updates the information contained in the accompanying prospectus. The second part is the accompanying prospectus,which provides more general information, some of which may not apply to this offering. Generally, when we use the term “prospectus,” weare referring to both parts combined. You should read this entire prospectus supplement as well as the accompanying prospectus and thedocuments incorporated by reference that are described under the “Where You Can Find More Information” section in this prospectus In making an investment decision, prospective investors must rely on their own examination of us and the terms of this offering, includingthe merits and risks involved. Neither we, the selling stockholders, the underwriters nor any of our or their respective representatives aremaking any representation to you regarding the legality of an investment in our common stock by you under applicable laws. You shouldconsult with your own advisors as to legal, tax, business, financial and related aspects of an investment in our common stock. Any statement made in this prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus willbe deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or inany other subsequently filed document that is also incorporated by reference into this prospectus modifies or supersedes that statement.Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus and any free writingprospectus is accurate only as of the date on its respective cover, regardless of the time of delivery of this prospectus supplement or anysale of our common stock, and that any information incorporated by reference herein or therein is accurate only as of the date of thedocument incorporated by reference, unless we indicate otherwise. You should not assume that the information